Similar Efficacy, Safety and CD4 T-cell Increase up to Week 96 Observed with Fostemsavir (FTR)-Based Regimens in the BRIGHTE Study and Dolutegravir (DTG)-Based Regimens in the VIKING-3 Study in Individuals with Multidrug-Resistant (MDR) HIV-1
Call 1-888-226-8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-332-1088 or www.fda.gov/medwatch
This site is intended for US Healthcare Professionals Only. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
Trademarks are owned by or licensed to the ViiV Healthcare group of companies.
©2025 ViiV Healthcare group of companies or its licensor. Produced in USA. February 2025